Drug Profile
Nepadutant
Alternative Names: MEN 11420Latest Information Update: 28 Jul 2017
Price :
$50
*
At a glance
- Originator Menarini
- Class Antiasthmatics; Antispasmodics; Cyclic peptides; Irritable bowel syndrome therapies
- Mechanism of Action Neurokinin 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Colic; Gastrointestinal disorders; Postoperative ileus
Most Recent Events
- 28 Jul 2017 Discontinued - Phase-II for Colic (In infants) in USA, Sweden, Poland, Germany, and Italy (PO), because Nepadutant was not listed on Menarini pipeline, July 2017
- 02 Jun 2015 Phase II development in Colic (infants) is ongoing in USA, Sweden, Poland, Germany and Italy
- 15 Nov 2010 Phase-II clinical trials in Colic in infants in Sweden (unspecified route)